Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Trogarzonon May 15, 2023 7:59pm
124 Views
Post# 35449358

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM was horrible

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM was horribleHe was brought onboard to do deals.  No deals after 3 years.  Irresponsible spending that the board did not do it's job of containing with the result we now have a worthless pipeline and 65M usd of dept at 15% that will choke the company for a long time if not kill it..  Incompentence in communications and shareholder relations with the result we now have a penny stock on the Nasdaq and lets not forget a possible delisting unless they render our shares even more worthless by regrouping them to magically returm above 5$. What more can be said about that person that seems more interested by his personal agenda that the company itself.  I mean I was'nt alone to read the recent article of biotech magazine in witch he clearly makes a list of not to do as a new biotech CEO learned from his elm at Thera.  Like he's giving advice to others on what to avoid from he learned of his mistakes at Thera.  That is when he does'nt promote some environment cause with Thera in the background, like what is the link and don't you have anything more important to do for my 2M+ a year.
<< Previous
Bullboard Posts
Next >>